<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02532036</url>
  </required_header>
  <id_info>
    <org_study_id>TB040</org_study_id>
    <nct_id>NCT02532036</nct_id>
  </id_info>
  <brief_title>MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) Infection</brief_title>
  <official_title>A Phase I Trial to Compare the Safety and Immunogenicity of Candidate TB Vaccine MVA85A Administered by the Aerosol Inhaled Route and the Intramuscular Route in Healthy Adult Volunteers Who Are Latently Infected With Mycobacterium Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TB040 is a clinical trial to investigate and compare the effects of a candidate Tuberculosis
      (TB) vaccine, MVA85A, administered by the aerosol inhaled route and the intramuscular route
      in healthy adult volunteers who are latently infected with Mycobacterium tuberculosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AE)</measure>
    <time_frame>Up to Day 168</time_frame>
    <description>Collection of AE data at each visit and via diary card after vaccination visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Laboratory markers of immunity</measure>
    <time_frame>Up to Day 168</time_frame>
    <description>Evaluation of ex-vivo ELISpot and intracellular cytokine staining in blood and bronchoalveolar lavage (BAL) samples.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Transcriptomics analysis</measure>
    <time_frame>Up to Day 168</time_frame>
    <description>Analysis of transcriptomics and exploratory markers of immunity in blood and BAL samples.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Starter Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive 1x10^7 pfu aerosol inhaled MVA85A at day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive 5x10^7 pfu aerosol inhaled MVA85A, and intramuscular saline placebo both at day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive 5x10^7 pfu intramuscular MVA85A, and aerosol inhaled saline placebo both at day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aerosol inhaled MVA85A</intervention_name>
    <arm_group_label>Starter Group</arm_group_label>
    <arm_group_label>Group A</arm_group_label>
    <other_name>MVA85A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intramuscular MVA85A</intervention_name>
    <arm_group_label>Group B</arm_group_label>
    <other_name>MVA85A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intramuscular Saline placebo</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aerosol inhaled Saline placebo</intervention_name>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Volunteers must meet all of the following criteria to enter the trial:

          -  Healthy adult aged 18-55 years

          -  Resident in or near Oxford, Birmingham or London for the duration of the trial period

          -  Screening IGRA positive

          -  Ineligible for chemoprophylaxis for latent M.tb infection, declined prophylaxis or
             considered low risk due to distant contact history

          -  Chest Computed Tomography (CT) normal; or abnormal with features consistent with
             primary M.tb infection but no features suggestive of active disease

          -  No relevant findings in medical history or on physical examination

          -  Allow the Investigators to discuss the individual's medical history with their General
             Practitioner

          -  Use effective contraception for the duration of the trial period (females only)

          -  Refrain from blood donation during the trial

          -  Give written informed consent

          -  Allow the Investigator to register volunteer details with a confidential database (The
             Over-volunteering Protection Service) to prevent concurrent entry into clinical trials

          -  Able and willing (in the Investigator's opinion) to comply with all the trial
             requirements

        Exclusion Criteria:

        Volunteers must meet none of the following criteria to enter the trial:

          -  Participation in another research study involving receipt of an investigational
             product in the 30 days preceding enrolment, or planned use during the trial period

          -  Prior vaccination with candidate vaccine MVA85A, candidate vaccine FP85A,any other
             recombinant MVA vaccine or any other candidate TB vaccine

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the planned trial vaccination date

          -  Clinically significant history of skin disorder, allergy, atopy, immunodeficiency
             (including HIV), cancer (except BCC or CIS), cardiovascular disease, gastrointestinal
             disease, liver disease, renal disease, endocrine disorder, neurological illness,
             psychiatric disorder, drug or alcohol abuse

          -  Concurrent oral or systemic steroid medication or the concurrent use of other
             immunosuppressive agents

          -  History of anaphylaxis to vaccination or any allergy likely to be exacerbated by any
             component of the trial vaccine, sedative drugs, or any local or general anaesthetic
             agents

          -  Pregnancy, lactation or intention to become pregnant during trial period

          -  Any respiratory disease, including asthma

          -  Current smoker

          -  Clinically significant abnormality on screening CT thorax

          -  Clinically significant abnormality of pulmonary function tests

          -  Any nasal, pharyngeal, or laryngeal finding which precludes bronchoscopy

          -  Current use of any medication taken through the nasal or inhaled route including
             cocaine or other recreational drugs

          -  Clinical, radiological, or laboratory evidence of current active TB disease

          -  Past treatment for TB disease

          -  Any clinically significant abnormality of screening blood or urine tests

          -  Positive HBsAg, HCV or HIV antibodies

          -  Any other significant disease, disorder, or finding, which, in the opinion of the
             Investigator, may either put the volunteer at risk, affect the volunteer's ability to
             participate in the trial or impair interpretation of the trial data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen McShane</last_name>
    <role>Study Director</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Moss</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Lipman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Free Hostpital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felicity Perrin</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College Hospital NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julia Marshall</last_name>
    <email>julia.marshall@ndm.ox.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Mashall</last_name>
      <phone>01865 611413</phone>
      <email>julia.marshall@ndm.ox.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Helen McShane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Warin Ward, Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Riste</last_name>
      <email>vaccinetrials@ndm.ox.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Helen McShane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NIHR Wellcome Trust Clinical Research Facility, University of Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Marshall</last_name>
      <phone>01865 611413</phone>
      <email>julia.marshall@ndm.ox.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Paul Moss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NIHR/Wellcome Trust King's Clinical Research Facility</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Marshall</last_name>
      <phone>020 3299 1851</phone>
      <email>kingscrf@kcl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Felicity Perrin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisha Pickett</last_name>
      <phone>020 7794 0500</phone>
      <phone_ext>34301</phone_ext>
      <email>elisha.pickett@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Marc Lipman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2015</study_first_submitted>
  <study_first_submitted_qc>August 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2015</study_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MVA85A</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Aerosol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

